Skip to main content
Premium Trial:

Request an Annual Quote

Sangamo Hopes to Corner Zinc Finger Market with Acquisition of Gendaq

NEW YORK, May 31 - Sangamo Biosciences's acquisition of Gendaq will allow the company to corner the market on zinc finger protein technology as well as to stave off any potential patent disputes, company executives said Thursday.

"Gendaq really represents the one piece of scientific thinking that was not part of our family," Casey Case, Sangamo's vice president for research, told GenomeWeb. "It's great to have them in the fold."

Sangamo Biosciences said Wednesday it had obtained the option to acquire privately-held Gendaq in a stock-for-stock deal worth $39.7 million. The company is currently doing due diligence on Gendaq. 

Julianna Wood, senior director of corporate communications for Sangamo, also noted that since Sangamo was awarded a patent in the UK covering the application of ZFP technology to gene regulation, it made sense for the two companies to discuss merging their businesses as a way of avoiding lengthy and costly patent disputes.

Gendaq was developing a "complementary approach" to applying ZFP technology to gene regulation, said Case. 

While Case and Wood expressed enthusiasm for working with Yen Choo, a scientist at Gendaq who developed many of the early principles for engineering zinc finger proteins, Wood said it was too early to comment on the role Gendaq's scientists would play in the new organization.

"It's always good to get the premier thought leaders involved," Wood said, "but it's premature to talk about how the organization will be structured."

Separately, one of Sangamo's academic collaborators, Frank Giordano, a cardiologist at the Yale University School of Medicine, presented results at a conference in Seattle on Thursday showing that ZFP technology could up-regulate the expression of a gene associated with new blood vessel growth, Wood said. The demonstration, while only in a mouse model, could lead to therapeutic applications for ZFP technology in cardiovascular disease.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.